Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

11.07
+0.17001.56%
Post-market: 11.070.00000.00%19:31 EDT
Volume:272.43K
Turnover:3.02M
Market Cap:510.26M
PE:-3.74
High:11.23
Open:10.95
Low:10.91
Close:10.90
Loading ...

Company Profile

Company Name:
Urogen Pharma Ltd.
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
235
Office Location:
400 Alexander Park Drive,4th Floor,Princeton,New Jersey,United States
Zip Code:
08540
Fax:
- -
Introduction:
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Directors

Name
Position
Arie Belldegrun
Chairman of the Board
Elizabeth Barrett
Director and Chief Executive Officer
Cynthia M. Butitta
Director
Daniel Wildman
Director
Fred E. Cohen
Director
James A. Robinson, Jr
Director
Leana S. Wen
Director
Stuart Holden
Director

Shareholders

Name
Position
Elizabeth Barrett
Director and Chief Executive Officer
Don Kim
Chief Financial Officer
Jason Smith
General Counsel and Chief Compliance Officer
Mark P. Schoenberg
Chief Medical Officer